For investors looking for growth, biotech stocks are a great place to start one’s search. This is a sector that’s seen its valuation multiples decline in many cases to a greater extent than the overall market. Thus, while many biotech stocks exhibit strong growth trajectories, these companies often trade at bargain prices. Much of that has…

A stock that scores a perfect 10 should be on every investor’s list of stocks to buy. Any company that receives full marks on quality, value, or growth are stocks I’d considering a perfect 10. For this article, I’m using StockRover’s stock screening tool, which screens for such qualities among a very large basket of…

The Dow Jones Industrial Average is down around 6.2% year to date. Of the 30 stocks in the index, 14 are down at least 10% for the year. That should make it relatively easy to find undervalued Dow stocks to buy. However, the index has made gains in recent weeks, rising more than 8.4% in…

The stock market is on a long-term downtrend as interest rates rise and inflation remains high despite a slight cool-off. Many retirement portfolios that invest in indexes such as S&P500 are down at least 17% year-to-date. That is even more awful when you add inflation to the equation. Of course, no stock is immune to…

My task today is to find seven of the most undervalued long-term stocks to buy now. We need to determine two things before stock selection takes place. First, it’s important to define what is meant by long-term. Secondly, we need to classify what makes a stock undervalued. Every person’s opinion on this subject is different.…

Since the early-2020 onset of the Covid-19 pandemic, pharmaceutical giant Merck (NYSE:MRK) hasn’t generally been the center of attention. On Wall Street, there hasn’t been much buzz about MRK stock as the company’s competitors stole the spotlight. However, with a new Covid-19 treatment gaining traction, this could be changing. Source: Shutterstock Competition can be a…

The lockdowns have not been part of the conversation for a long while. They are resurfacing now as we heard rumblings last week. Last year, the pandemic forced the whole world into a giant halt. That decimated the profit-and-loss statements of millions of businesses. Nevertheless, even back then there were stocks to buy on the…

The smartest CEO in America today is a Greek veterinarian named Albert Bourla, CEO of Pfizer (NYSE:PFE). Source: Manuel Esteban / Shutterstock.com Bourla has made Pfizer stock a hot ticket. The stock is up 38% so far in 2021, generating $100 billion in new market capitalization. He has done this with a drug Pfizer didn’t…

Spin-off stocks have been in the limelight in recent weeks. For instance, Johnson & Johnson (NYSE:JNJ) recently announced it will spin off its consumer health division and instead focus on pharmaceuticals and medical devices. Similarly, General Electric (NYSE:GE) announced plans to separate into three different companies, focusing on aviation, health care and energy. A stock…

Before the COVID-19 pandemic, Merck (NYSE:MRK) stock was a good one to own. The performance of Merck stock matched that of the S&P 500, and it paid a steadily rising dividend. Source: Atmosphere1 / Shutterstock.com Since then, the obsession with growth and vaccines has told a different story. Over the last two years the average…

Things appear to have gone from bad to worse for high-flying pharmaceutical company Moderna (NASDAQ:MRNA) stock, leaving shareholders reeling. Source: Ascannio / Shutterstock.com MRNA stock has cratered, dropping from $350 a share all the way down to $228. The steep fall came after the company reported disappointing quarterly results that shocked Wall Street and revised down…

As recently as late October, it seemed like Novavax (NASDAQ:NVAX) was becoming an “also ran” in the vaccine horse race. For weeks, investors were bailing out of NVAX stock on news of Merck’s (NYSE:MRK) antiviral Covid-19 pill plus reports of NVAX facing production headwinds. Source: Ascannio/Shutterstock.com But now, as positive news is starting to come out? It…

Covid-19 vaccine giant Moderna (NASDAQ:MRNA) has been on a tear since the second quarter of 2020.  It has grown its top line by over 6,500% on a year-over-year basis due to rampant sales of its Covid-19 vaccine. As a consequence, it now trades at a whopping valuation hardly justified by its long-term outlook. The lack of…

Analyst upgrades as well as downgrades typically get stock investors’ attention on Wall Street. When analysts upgrade companies, a ‘hold’, or neutral, opinion usually becomes a ‘buy’ conviction, with a new price target. And a downgrade involves an opposite move. Such a change in the conviction of a market professional who follows a given stock…

Investors in the vaccine maker Novavax (NASDAQ:NVAX) stock witnessed rollercoaster trading in September and October. Source: Ascannio/Shutterstock.com NVAX stock ended August shy of $240. By Sept. 8, the shares approached $280. Yet now, they are hovering just below $150. In other words, the record high of $331.68 seen in early February is now in the…

The last time I wrote about Novavax (NASDAQ:NVAX) was in early October. NVAX stock was getting hammered on the news Merck (NYSE:MRK) and Ridgeback Biotherapeutics were developing an antiviral Covid-19 pill. I suggested its stock was cursed. Source: Ascannio/Shutterstock.com Fast forward to the end of October. Novavax stock was reeling once more due to the…

Up until now, I’ve been bullish on Covid-19 vaccine play Novavax (NASDAQ:NVAX). I felt its international order backlog made up for its lack of progress in entering the U.S. market. This pointed to further upside for NVAX stock, as investors were not fully pricing in future earnings. Source: Shutterstock Even with news of Merck’s (NYSE:MRK)…

Novavax (NASDAQ:NVAX) continues to be a wild ride for investors. NVAX stock has lost some 35% of its value since the end of September. In general, vaccine stocks have dropped upon the news of Merck’s (NYSE:MRK) Covid-19 pill. Source: Ascannio/Shutterstock.com Further weighing down on NVAX stock is large insider selling. The company’s CEO, Stanley Erck,…